WO2005036990A1 - Composition de prevention, d'inhibition et de traitement de l'obesite et de maladies relatives - Google Patents

Composition de prevention, d'inhibition et de traitement de l'obesite et de maladies relatives Download PDF

Info

Publication number
WO2005036990A1
WO2005036990A1 PCT/EP2004/010907 EP2004010907W WO2005036990A1 WO 2005036990 A1 WO2005036990 A1 WO 2005036990A1 EP 2004010907 W EP2004010907 W EP 2004010907W WO 2005036990 A1 WO2005036990 A1 WO 2005036990A1
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
treatment
composition
food product
mammals
Prior art date
Application number
PCT/EP2004/010907
Other languages
English (en)
Inventor
Nathalie Maria Delzenne
Patrice Daniel Cani
Anne Frippiat
Original Assignee
Tiense Suikerraffinaderij N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiense Suikerraffinaderij N.V. filed Critical Tiense Suikerraffinaderij N.V.
Publication of WO2005036990A1 publication Critical patent/WO2005036990A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/24—Cellulose or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the invention relates to the use of a combination of a fermentable dietary fibre and a food product for the manufacture of a composition for the prevention, inhibition of development and treatment of obesity and obesity-related diseases in humans and mammals, and to a method for same.
  • BMI Body Mass Index
  • Overweight is commonly associated with some undesirable aspects and effects, essentially with cosmetic aspects, such as an undesirable bodily appearance, but also with some undesirable physical effects on the body resulting from a higher than normal load on bodily systems, including on muscles, tendons, joints, and various organs and systems, in particular the cardiovascular system.
  • the physical effects of overweight commonly being low to moderate, are not considered as health impairing effects.
  • conditions of overweight gradually move to conditions of obesity.
  • overweight entails essentially undesirable cosmetic aspects
  • obesity entails undesirable cosmetic aspects as well as various undesirable effects on health.
  • obesity has been identified as an important factor in the genesis, development and/or evolution of various diseases, herein indicated as obesity-related diseases, including cardiovascular diseases, hyperglycemia, diabetes, steatosis, hypertriglyceridemia, osteoarthritis, hypertension, lung disease and cancer, particularly bowel and breast cancer.
  • cardiovascular diseases including cardiovascular diseases, hyperglycemia, diabetes, steatosis, hypertriglyceridemia, osteoarthritis, hypertension, lung disease and cancer, particularly bowel and breast cancer.
  • Undesirable effects on health also include undesirable conditions, such as hypertension, as well as cardiovascular accidents, such as stroke.
  • the condition of obesity as such has in fact be considered as an impairment, ailment, dysfunction, disorder and/or disease with needs therapeutic treatment in order to inhibit or reduce the dysfunctions and health impairing effects of obesity and/or to maximally restore impaired bodily systems and functions .
  • the undesirable cosmetic aspects of overweight and obesity typically relating to bodily appearance, are clearly differentiated from the undesirable impact of obesity on health, including the undesirable impairment and effects of obesity on bodily functions and systems, as well as the effects of obesity on health through resulting obesity-related diseases . Because obesity is still steadily increasing, it tends to become a pandemic that threatens health and well-being of a large part of the population worldwide .
  • Analogue to humans mammals, particularly domesticated mammals, including pets such as dogs and cats, appear to present a similar pattern with respect to the development and evolution of overweight, obesity and obesity-related undesirable conditions and diseases. So in this respect, for mammals considerations analogue to the ones for humans apply. Accordingly, in view of the undesirable effects of overweight and the health threats resulting from obesity, significant research efforts are continuously made worldwide to elucidate the mechanisms leading to overweight and obesity in order to find methods for preventing, inhibiting and treating overweight, obesity, and obesity- related diseases.
  • appetite-stimulating hormones and food intake-inhibiting hormones (i.e. appetite-inhibiting hormones).
  • Identified food intake-stimulating hormones comprise i . a . neuropeptide Y (NPY) , agouti-related peptide (AgRP) , and the recently discovered ghrelin
  • food intake- inhibiting hormones comprise i . a . leptin and glucagon-like peptide-1 (GLP-1) .
  • Ghrelin is described by K. Kojima et al., (Current
  • Ghrelin is disclosed to be an appetite-regulating hormone with a peptide structure that is produced mainly in the stomach, and ghrelin peptides have already been identified in several mammals .
  • Rat and human ghrelin peptides were found to consist both of 28 amino acids, differing only in two amino acid residues. Both ghrelin peptides are bearing a n-octanoyl group at the Ser 3 amino acid unit, a structure which is essential for the activity of ghrelin.
  • Ghrelin was found to be appetite-stimulating when administered centrally as well as peripherally.
  • the main active site of ghrelin was found to be the hypothalamic arcuate nucleus, which is also the target site of leptin (an appetite-suppressing hormone from adipose tissues) , as well as of neuropeptide Y (NPY) and agouti- related protein (AgRP) (both appetite-stimulating peptides produced in the arcuate nucleus) .
  • leptin an appetite-suppressing hormone from adipose tissues
  • NPY neuropeptide Y
  • AgRP agouti- related protein
  • the appetite-stimulating effects of both NPY and AgRP were found to be inhibited directly by leptin.
  • the appetite-stimulating effect of ghrelin was found to be blocked by an NPY receptor antagonist.
  • IV injection of ghrelin was found to stimulate neurons that contained NPY and/or AgRP in the hypothalamus (M. Kojima et al . , o . c , p. 666-667). These results indicate that ghrelin increases feeding activity by stimulating NPY- and AgRP-containing neurons in the hypothalamus to promote the production and secretion of NPY- and AgRP peptides. Accordingly, ghrelin was found to stimulate food intake and to be a natural antagonist to leptin (M. Kojima et al . , o . c. , p. 667) . Regulation of ghrelin secretion appears to be controlled by feeding.
  • Plasma ghrelin concentrations of normal subjects show a diurnal pattern with preprandrial increases and postprandrial decreases (T. Shiiya et al . , Journal of Clinical Endocrinology and Metabolism, Vol. 87(1) , 240-244, (2002) ) .
  • ghrelin is a gastro-intestinal released hormone that circulates in the bloodstream and transmits appetite- stimulating signals from peripheral, gastro-intestinal organs to the brain, in particular to the appetite- regulating regions in the hypothalamus.
  • energy and metabolic processes in humans and mammals may be controlled by modulating a balance between factors or hormones that regulate appetite in a negative and a positive manner.
  • J. Nedvidkova et al. (o.c, p. 1680, left column) disclose that, after overnight fasting, the consumption of a standardised breakfast (containing fat, proteins and carbohydrates) or non-caloric Psyllium fibre were about equally effective in reducing plasma ghrelin levels in healthy subjects during a certain period of time after food-intake, named post-absorptive or postprandial period, the inventors have surprisingly found that, as the result of the intake of a composition comprising a combination of a fermentable dietary fibre and a food product, the plasma ghrelin level in rats remains lower in the post-absorptive period for at least 8 hours, compared to controls.
  • Controls herein is meant subjects that have consumed only said food product and did not consume any fibres except the non-fermentable cellulose fibres present in said food product that constituted the normal diet . Having regard to the analogy between rats and humans with respect to ghrelin, said findings have led to the present invention.
  • Said findings provide the possibility to control and/or suppress plasma ghrelin levels in humans and mammals, and, according to the invention, to utilise said combination of a fermentable dietary fibre and a food product to inhibit the synthesis and/or release of ghrelin, to control plasma ghrelin levels, and to suppress plasma ghrelin levels, particularly during a post-absorptive period of at least 8 hours, and consequently to suppress the effects of the appetite-stimulating ghrelin hormone, to control food-intake behaviour, particularly by the suppression of food-intake, and to reduce the risk of development, to prevent and/or to inhibit the development of overweight, obesity and obesity-related conditions and diseases, as well as to treat overweight and obesity, in humans and mammals.
  • the present invention provides in one aspect the use of a combination of a fermentable dietary fibre and a food product for the manufacture of a composition for oral administration or tube feeding, for the reduction of the risk of development, the prevention, the inhibition of the development, or for the treatment of obesity and/or obesity-related diseases in humans and mammals, said food product comprising at least two components of conventional food products selected from the group of components consisting of proteins, digestible carbohydrates and fat .
  • the present invention provides the use of said combination of a fermentable dietary fibre and a food product for the manufacture of a composition for oral administration or tube feeding, for the reduction of the risk of development, the prevention, the inhibition of the development, or the treatment of obesity and obesity- related diseases in humans and mammals by suppressing plasma ghrelin levels, and/or by the inhibition of the synthesis and/or release, and/or the effects of the appetite-stimulating hormone ghrelin in humans and mammals.
  • the present invention provides the use of said combination of a fermentable dietary fibre and a food product for the manufacture of a composition for oral administration or tube feeding, for the reduction of the risk of development, the prevention, the inhibition of the development, or the treatment of obesity and/or obesity-related diseases in humans and mammals by suppressing plasma ghrelin levels and/or by maintaining a lower plasma ghrelin level in humans and mammals, compared to controls having consumed only said food product, in the post-absorptive period for at least 8 hours.
  • the present invention provides the use of said combination of a fermentable dietary fibre and a food product for the manufacture of a composition for oral administration or tube feeding, for the reduction of the risk of development, the prevention, the inhibition of the development, or the treatment of obesity-related diseases in humans and mammals by the prevention, the inhibition of the development, or the treatment of obesity.
  • the present invention provides the use of said combination of a fermentable dietary fibre and a food product for the manufacture of a composition for oral administration or tube feeding, for the reduction of the risk of development, the prevention, the inhibition of the development, or the treatment of obesity and obesity- related diseases in humans and mammals, by the suppression of food-intake .
  • the invention provides a cosmetic treatment for the prevention, the inhibition of the development, or the treatment of overweight and/or obesity in humans and mammals comprising administering orally or through tube feeding to a subject in need of such treatment a composition comprising an effective amount of said combination of a fermentable dietary fibre and a food product .
  • the present invention provides a method for the suppression of plasma ghrelin levels, and/or the inhibition of the synthesis and/or release of ghrelin, and/or the inhibition of the effects of the appetite-stimulating hormone ghrelin in humans and mammals by administering orally or by tube feeding to a being in need of such treatment a composition comprising a an effective amount of said combination of a fermentable dietary fibre and a food product.
  • the present invention provides a method for suppressing plasma ghrelin levels and/or for maintaining a lower plasma ghrelin level in humans and mammals compared to controls, in the post-absorptive period for at least 8 hours, by administration orally or through tube feeding to a subject in need of such treatment a composition comprising an effective amount of said combination of a fermentable dietary fibre and a food product, the controls having consumed only said food product .
  • the present invention provides a method for the reduction of the risk of development, the prevention, the inhibition of the development, or for the treatment of overweight, obesity and/or obesity-related diseases in humans and mammals, by administering orally or by tube feeding to a subject in need of such treatment a composition comprising a an effective amount of said combination of a fermentable dietary fibre and a food product .
  • the present invention provides a method for the control of food-intake behaviour, in ⁇ particular for the inhibition of food-intake, in humans and mammals by administering orally or through tube feeding to a subject in need of such treatment a composition comprising an effective amount of said combination of a fermentable dietary fibre and a food product.
  • Mammals herein refers in particular to domesticated mammals, particularly pets, such as dogs and cats.
  • the composition according to the invention consists of said combination of a fermentable dietary fibre and a food product .
  • the composition according to the invention comprises said combination of a fermentable dietary fibre and a food product, and contains one or more further components, for example, a probiotic, a food supplement, vitamins, minerals, and trace elements.
  • Digestible carbohydrates are monomeric, oligomeric or polymeric carbohydrates or mixtures thereof that are metabolised by the enzymes of the digestive tract of respectively humans and mammals, and are essentially digested in the small intestine. They are well known in the art, and include e.g. sugars and most starches.
  • Fermentable dietary fibres are well known in the art too.
  • the term refers to carbohydrates that are resistant to hydrolysis by the enzymes of the digestive tract of respectively humans and mammals, but are fermented by bacteria in the large intestine, particularly bacteria of the genus Bifidus and the genus Lactobacillus . Fermentation is the process wherein bacteria utilise the carbohydrate as their primary energy source and metabolise it, thereby producing gases and short-chain fatty acids as by-products.
  • fermentable dietary fibre herein embraces soluble fibres as well as insoluble fibres (solubility in water at 25 °C, respectively, equal or more than 1 g/1 and less than 1 g/1) .
  • the fibres can be oligosaccharides as well as polysaccharides .
  • the difference between an oligosaccharide and a polysaccharide is based on the number of saccharide units building up the saccharide molecule.
  • a saccharide containing less than 10 saccharide units is named an oligosaccharide
  • polysaccharide refers to a carbohydrate that is built of 10 or more saccharide units.
  • Oligosaccharides can be products of nature as well as products derived from products of nature, for example by partial, enzymatic or acidic hydrolysis.
  • Oligosaccharides can also be obtained by enzymatic synthesis from saccharides, by enzymatic transformation of saccharides, and by chemical synthesis or chemical transformation of saccharides .
  • fermentable dietary fibre herein includes a mixture of fibre molecules of the same degree of polymerisation (homodisperse mixture) , a mixture of dietary fibre molecules of different degree of polymerisation (polydisperse mixture) , as well as a mixture of two or more dietary fibres of different chemical structure .
  • the term different chemical structure herein includes linear and branched molecules composed of the same saccharide units, as well as molecules composed of different saccharide units .
  • the term fermentable dietary fibre refers to a carbohydrate selected from the group consisting of pectins, including arabinans, galacturonans , galactans, arabino-galactans; hemi-celluloses, comprising xylanes and beta-glucans; gums, such as arabic gum, locust bean gum, guar gum and tragacanth; galactomannans ; carrageenans ; agar; alginates; resistant starch; fructans, such as levan-type fructans and inulin-type fructans, including inulin and oligofructose; and derivatives of said carbohydrates, such as oligo-fructosaccharides, oligo- galactosaccharides , oligo-xylosaccharides and oligo- glucosaccharides ; as well as any mixture of said fibres.
  • pectins including arabinans, galacturonans , galactans, arabino-gal
  • the dietary fibre is inulin or oligofructose (the latter being also termed interchangeably oligo-fructosaccharide or fructo- oligosaccharide) , which are both well known in the art.
  • Inulin is commonly obtained by extraction followed by purification according to conventional methods from plant sources, mainly from roots of chicory ( Cichorium intybus) , tubes of Jerusalem artichoke (Helianthus tuberosus) and Dahlia, and from the pifia (head) of the Blue Agave plant.
  • Oligofructose (fructo-oligosaccharide) is commonly obtained by partial hydrolysis of inulin, as well as by enzymatic synthesis from saccharose.
  • the dietary fibre is chicory inulin or oligofructose obtained from chicory inulin, preferably by partial enzymatic hydrolysis, or any mixture thereof .
  • Chicory inulin has a degree of polymerisation, namely the number of saccharide units in an inulin molecule, ranging from 2 to about 70.
  • Oligofructose has typically a degree of polymerisation ranging from 2 to 9.
  • Inulin as well as oligofructose is composed of polyfructose molecules that essentially consist of fructose units that are linked to each other mostly or exclusively by beta (2-1) fructosyl- fructose linkages .
  • the polyfructose chain may or may not end in a glucose unit.
  • inulin and oligofructose correspond to the general formula GFn or Fm, wherein G represents a glucose unit, F represents a fructose unit, and m and n are integers from 2 onwards .
  • a characterising parameter of inulin and oligofructose is the degree of polymerisation (represented by DP) , corresponding to the value of n + 1 or m.
  • Another characterising parameter is the number-average degree of polymerisation, represented by av.
  • DP or ( DP) which is the value corresponding to the total number of saccharide units (G and F) divided by the total number of inulin molecules present in a given sample, without taking into account the monomeric glucose and fructose and the dimeric saccharose that is present in the sample (H. Hoebregs, J. AOAC International, Vol.80 (5), 1029-1037, (1997) ) .
  • Chicory inulin obtained at industrial scale from roots of chicory, as well as oligofructose, typically obtained by partial enzymatic hydrolysis of chicory inulin, are available in various commercial grades, for example as RAFTILINE ® and RAFTILOSE ® (Trade names for respectively chicory inulin and oligofructose) from ORAFTI, Belgium.
  • Commercial grades of inulin comprise RAFTILINE ® ST, (with an av. DP of at least 10, typically of 10 to 13, and containing in total about 8 wt % glucose, fructose and sucrose) , RAFTILINE ® LS (with an av.
  • DP of at least 10, typically of 10 to 13, but containing in total less than 1 wt% glucose, fructose and sucrose
  • RAFTILINE ® HP which has an av. DP of at least 23, typically of 23 to 25, and is essentially free of glucose, fructose and sucrose
  • commercial grades of oligofructose comprise RAFTILOSE ® P95 which contains about 95 % by weight oligofructose with a DP ranging from 2 to 9 and which contains about 5 % by weight in total of glucose, fructose and sucrose.
  • Further suitable grades of inulin in accordance with the present invention include particular mixtures of oligofructose and long-chain inulin (inulin with av.
  • DP of at least 20, typically of 23 to 25 in a weight ratio ranging from 10/90 to 70/30, with a total content of inulin with a DP 9 and DP 10 of maximally 5 %, preferably maximally 3 % or even maximally 2 %, by weight, described in patent application WO 01/60176.
  • inulin grade is commercially available from ORAFTI (Belgium) , for example as RAFTILOSE ® Synergyl wherein said weight ratio of oligofructose and long-chain inulin of av. DP of 23 to 25 is about 1/1.
  • Agave inulin is commercially available for example as GAVEDIET ® PR with av.
  • Fructo-oligosaccharide (FOS) obtained by enzymatic synthesis from saccharose is for example commercially available as ACTILIGHT ® 950P (with > 95% of DP 3-5) from Beghin-Meiji Industries.
  • the term fat herein refers to fat or fats that occur as conventional fat component in food or feed products .
  • the term food product herein refers to any food product, typically to a conventional food product (intended for human consumption) or feed product (intended for animal consumption) , that contains at least two components of conventional food or feed products, selected from the group of components consisting of proteins, digestible carbohydrates and fat .
  • the term food product refers to a food or feed product that contains at least said three components .
  • the food product referred to herein usually, but not necessarily, comprises said components in a conventional balance .
  • the food product may be present in any conventional form, such as a liquid, a paste, a shaped solid.
  • said combination is composed of a mixture of a fermentable dietary fibre and two, three or more of said components of conventional food or feed products, it may be present too in any form, such as a liquid, a paste, a powder, or a shaped solid.
  • the combination of the fermentable dietary fibre and the food product, and the composition according to the invention can be obtained by conventional manufacturing processes, such as mixing of the fermentable dietary fibre and the food or feed product, and dry or wet mixing of the components, extrusion of the components, and co-spray- drying of the components forming the combination or the composition.
  • an additional component such composition can also be prepared by conventional techniques, for example by dry or wet mixing of all components at once, or by including the additional component into the separately prepared combination of the fermentable dietary fibre and the food product, or by mixing the additional component, the fermentable fibre and the food or feed product according to conventional techniques .
  • the composition according to the invention contains an effective amount of said combination of fermentable dietary fibre and food product.
  • effective amount is meant an amount that provokes a statistically significant suppression of plasma ghrelin levels in humans and mammals compared to controls having consumed only said food product, and that, accordingly, provokes a statistically significant lower plasma ghrelin level in humans and mammals compared to controls in the post-absorptive period, preferably for at least 8 hours .
  • the weight ratio fermentable dietary fibre / food product may range from 1/99 to 50/50, preferably from 2/98 to 30/70, more preferably from 5/95 to 30/70.
  • fermentable dietary fibre is meant for the calculation of said weight ratio, the total amount of fermentable dietary fibre that is present in the composition. So, if the food product or further components of the composition comprise a fermentable dietary fibre, said fibre is considered for the calculation of said weight ratio to be part of the fermentable dietary fibre component of the combination according to the present invention.
  • the preferred daily intake for humans of a composition according to the invention provides for a daily intake of fermentable dietary fibres ranging from 3 g to 50 g, preferably from 3 g to 30 g, more preferably 5 g to 15 g.
  • the daily intake of the composition can be obtained by the intake of one single unit dose, or by the intake of partial units spread over a one-day period that together correspond to the desired total daily intake .
  • the composition according to the present invention may be present in the form of a two-pack. Accordingly, the dietary fibre component may be present as such, or in association with an additional component, in a form that is separate from the food product.
  • Both components of the two-pack form are then taken or administered in such a manner that they are simultaneously present in the body so that they interact and provide the decreasing effect on plasma ghrelin levels that corresponds to the effect of the corresponding composition present in a one-pack form.
  • analogue considerations to the ones made above for humans apply, of course while taking into account the particulars of the concerned mammal species.
  • the invention is illustrated by the experiments given below.
  • Figure 1 shows the plasma ghrelin concentration in rats fed a standardised feed and the standardised feed + 10 wt % FOS in the post-absorptive period 8 hours after the last meal.
  • Figure 2 shows the weight of rats fed a standardised feed without and with fermentable dietary fibres in the post- absorptive period 8 hours after the last meal.
  • Figure 3 shows the evolution of the energy consumption of rats fed a standardised feed without and with fermentable dietary fibres during the experiment till sacrifice.
  • Figure 4 shows the weight of the epidydimal fat tissue, in % of the body weight, of rats fed standardised feed without and with fermentable dietary fibres at the sacrifice of the animals 8 hours after the last meal .
  • Figure 5 shows the plasma ghrelin concentration in rats fed standardised feed without and with fermentable dietary fibres at the sacrifice of the animals 8 hours after the last meal .
  • Plasma ghrelin concentration was measured according to the method described by Linco Research, Active Ghrelin RIA Kit, USA. The results are presented in Figure 1 below, and show that the plasma ghrelin concentration was significantly lower 8 hours after the last meal in rats fed meals containing fermentable dietary fibres (FOS group) , than in the control rats (CT group) . Accordingly, the lower plasma ghrelin concentration in the group fed meals containing fermentable dietary fibres can be considered as an indicator of satiety maintenance, effecting food-intake behaviour by postponing the impulses and tendency for food intake compared to the control group.
  • compositions of the invention suppress food intake and hence have an inhibitory effect on the development of overweight, obesity and accordingly on obesity-related undesirable conditions and diseases. Furthermore, it can be concluded that the compositions of the invention are suitable for the treatment of overweight and obesity.
  • compositions according to the present invention comprising a combination of a fermentable dietary fibre and a food product as defined hereinabove, is suitable for suppressing plasma ghrelin levels and for maintaining post-absorptive reduced plasma ghrelin levels in humans and mammals compared to controls that took only said food product without fermentable dietary fibres .
  • the results also show that the compositions are able to inhibit the production and/or release of ghrelin in humans and mammals, and thus to provoke inhibiting effects on appetite and hence on food intake and energy intake.
  • compositions of the invention are suitable to prevent and/or inhibit the development of overweight and obesity, and thus also of obesity-related undesirable conditions and diseases, as well as to provoke a reduction of overweight and obesity, and accordingly a reduction of obesity-related undesirable conditions and diseases.
  • These results also support the method according to the present invention for suppressing the plasma ghrelin concentration in humans and mammals, for inhibiting the synthesis and/or release of ghrelin, and for suppressing the effects of the appetite-stimulating hormone ghrelin, and, accordingly also the method for the prevention, inhibition and treatment of overweight, obesity and obesity-related undesirable conditions and diseases in humans and mammals, said method involving administration of a composition comprising an effective amount of a combination of a fermentable dietary fibre and a food product as defined hereinabove.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'une combinaison d'une fibre alimentaire pouvant être fermentée et d'un produit alimentaire destiné à la fabrication d'une composition destinée à l'administration orale ou à l'alimentation par sonde, aux fins de prévention, inhibition du développement et du traitement de l'obésité et de maladies relatives à l'obésité chez des êtres humains et des mammifères. La composition inhibe la synthèse et/ou la libération et les effets de l'hormone stimulant l'appétit, la ghréline, et provoque une suppression des niveaux de la ghréline plasmatique qui, durant la période suivant l'absorption, 8 heures après la prise, sont, de préférence, au moins 30 % inférieurs à la concentration en ghréline plasmatique chez des groupes témoins ayant consommé uniquement le produit alimentaire. L'invention concerne également une méthode de prévention, d'inhibition du développement et du traitement du surpoids, de l'obésité et de maladies relatives à l'obésité chez des êtres humains et des mammifères. L'invention concerne, en outre, un procédé permettant de supprimer des niveaux de ghréline plasmatique, aux fins d'inhibition de la synthèse et/ou libération et les effets de l'hormone de stimulation de l'appétit, la ghréline, chez des êtres humains et des animaux. Les procédés consistent en une prise orale ou une alimentation par sonde d'une composition comprenant la combinaison d'une fibre alimentaire pouvant être fermentée et du produit alimentaire.
PCT/EP2004/010907 2003-09-30 2004-09-30 Composition de prevention, d'inhibition et de traitement de l'obesite et de maladies relatives WO2005036990A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03022007A EP1520486A1 (fr) 2003-09-30 2003-09-30 Composition et procédé de suppression de ghrelin
EP03022007.3 2003-09-30

Publications (1)

Publication Number Publication Date
WO2005036990A1 true WO2005036990A1 (fr) 2005-04-28

Family

ID=34306791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010907 WO2005036990A1 (fr) 2003-09-30 2004-09-30 Composition de prevention, d'inhibition et de traitement de l'obesite et de maladies relatives

Country Status (2)

Country Link
EP (1) EP1520486A1 (fr)
WO (1) WO2005036990A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120813A1 (fr) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation Utilisation combinée de composé inhibiteur de dipeptidylpeptidase iv, et d'adoucisseur
CN113893268A (zh) * 2021-11-18 2022-01-07 河南中大恒源生物科技股份有限公司 金针菇子实体膳食纤维、提取方法及其在制备减重药物或治疗肥胖症药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527556A (en) * 1991-10-04 1996-06-18 Raffinerie Tirlemontoise S.A. Compositions having a creamy structure and containing fructan, process for preparing these compositions and their use
WO2002071857A1 (fr) * 2001-03-12 2002-09-19 Bristol-Myers Squibb Company Compositions de confiserie contenant une ou plusieurs fibre(s)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527556A (en) * 1991-10-04 1996-06-18 Raffinerie Tirlemontoise S.A. Compositions having a creamy structure and containing fructan, process for preparing these compositions and their use
WO2002071857A1 (fr) * 2001-03-12 2002-09-19 Bristol-Myers Squibb Company Compositions de confiserie contenant une ou plusieurs fibre(s)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEDVÍDKOVÁ, JARA: "Loss of Meal-Induced decrease in Plasma Ghrelin Levels in Patients with Anorexia Nervosa", THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 88, no. 4, 2003, pages 1678 - 1682, XP008027633 *
WREN A M ET AL: "Ghrelin enhances appetite and increases food intake in humans", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 86, no. 12, December 2001 (2001-12-01), pages 5992 - 5995, XP002265244, ISSN: 0021-972X *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120813A1 (fr) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation Utilisation combinée de composé inhibiteur de dipeptidylpeptidase iv, et d'adoucisseur
JPWO2008120813A1 (ja) * 2007-04-03 2010-07-15 田辺三菱製薬株式会社 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
AU2008233548B2 (en) * 2007-04-03 2011-12-01 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
US8927504B2 (en) 2007-04-03 2015-01-06 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
CN113893268A (zh) * 2021-11-18 2022-01-07 河南中大恒源生物科技股份有限公司 金针菇子实体膳食纤维、提取方法及其在制备减重药物或治疗肥胖症药物中的应用

Also Published As

Publication number Publication date
EP1520486A1 (fr) 2005-04-06

Similar Documents

Publication Publication Date Title
Khartourn Antidiabetic effects of fenugreek (Trigonella foenum-graecum) seeds in the domestic rabbit (Oryctolagus cuniculus)
Scheppach et al. Addition of dietary fiber to liquid formula diets: the pros and cons
US20030064937A1 (en) Composition for reducing appetite in mammals
Jangra et al. Ameliorative effect of fermentable fibres on adiposity and insulin resistance in C57BL/6 mice fed a high-fat and sucrose diet
CN104093413A (zh) 治疗糖尿病和/或肥胖症的组合物和方法
CN108024977A (zh) 用于治疗肥胖症和肥胖症相关疾病的包含卡格列净和芬特明的协同治疗
AU777044B2 (en) Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars"
WO2019235099A1 (fr) Aliment fonctionnel
US20120058938A1 (en) Nutritional composition inducing a postprandial endocrine response
Suzuki et al. Effect of dietary fiber-enriched brown rice crackers on suppressing elevation of blood glucose level
EP1520486A1 (fr) Composition et procédé de suppression de ghrelin
Bortolotti et al. Effect of a balanced mixture of dietary fibers on gastric emptying, intestinal transit and body weight
Fahey Jr et al. The role of dietary fibre in companion animal nutrition
EP4147706A1 (fr) Composition régulatrice du système neuro-endocrinien-immunitaire
CA3091729A1 (fr) Composition de glp-1 pour le traitement de l'obesite et la gestion du poids
JP2010059084A (ja) 機能性食品及び医薬
CN112715961A (zh) 一种有助于老年糖尿病人增肌的食品组合物
CN104721192A (zh) 一种包含氯卡色林的药物组合物及其医药用途
Dakam et al. Effects of sodium bicarbonate and albumin on the in vitro water-holding capacity and some physiological properties of Trigonella foenum graecum L. galactomannan in rats
CN103750330B (zh) 一种含有牛骨髓粉的口服组合物及其制备方法
CN114177163B (zh) 一种治疗高血压的药物
CN114304631A (zh) 一种降糖营养补充剂及其制备方法与应用
EP1964558A1 (fr) Compositions pharmaceutiques renfermant des substances inhibitrices des lipases intestinales combinees a un complexe ou o-coordonne de dinicotinate de chrome utilise dans le traitement et la lutte contre l'obesite et le surpoids
CN106389439A (zh) 一种治疗肝硬化腹水的中西药组合及其制备方法和应用
BR102020016156A2 (pt) Composição reguladora do sistema neuro-imune-endócrino

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase